Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

v3.20.4
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Other Comprehensive Gain (loss) [Member]
Accumulated Deficit [Member]
Series A Convertible Preferred Stock [Member]
Series B Convertible Preferred Stock [Member]
Total
Balance, at beginning at Dec. 31, 2018   $ 212,157 $ (41) $ (188,452)     $ 23,664
Balance, at beginning (in shares) at Dec. 31, 2018 328,689       9,856    
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock upon conversion of Series A Convertible preferred stock $ 1 (1)          
Issuance of common stock upon conversion of Series A Convertible preferred stock (in shares) 281,610       (9,856)    
Issuance of common stock in exchange for exercise of warrants in March 2019 ($35.00 per share)   70         70
Issuance of common stock in exchange for exercise of warrants in March 2019 ($35.00 per share) (in shares) 2,000            
Issuance of common stock under 2018 Purchase Agreement   387         387
Issuance of common stock under 2018 Purchase Agreement (in shares) 22,754            
Issuance of common stock under At-the-market offering, net of transactional expenses of $1   33         33
Issuance of common stock under At-the-market offering, net of transactional expenses of $1 (in shares) 2,106            
Issuance of common stock under 2019 Purchase Agreement, net of transactional expenses of $916 $ 1 4,483         4,484
Issuance of common stock under 2019 Purchase Agreement, net of transactional expenses of $916 (in shares) 900,000            
Issuance of commitment shares in August 2019 (in shares) 35,529            
Issuance of Series A Convertible preferred stock and common stock warrants in November 2019 ($1,000.00 per share, net of transactional expenses of $957)   6,980         6,980
Issuance of Series A Convertible preferred stock and common stock warrants in November 2019 ($1,000.00 per share, net of transactional expenses of $957) (in shares)         7,938    
Beneficial conversion feature in connection with issuance of Series A Convertible preferred stock   2,474         2,474
Preferred stock deemed dividend   (2,474)         (2,474)
Issuance commitment under 2020 Purchase Agreement   387         387
Issuance of common stock and common stock warrants in November 2019 ($1.94 per share, net of transaction expenses of $128) $ 1 933         934
Issuance of common stock and common stock warrants in November 2019 ($1.94 per share, net of transaction expenses of $128) (in shares) 547,420            
Issuance of common stock upon conversion of Series A Convertible preferred stock $ 4 (4)          
Issuance of common stock upon conversion of Series A Convertible preferred stock (in shares) 4,091,753       (7,938)    
Issuance of common stock in exchange for exercise of cashless warrants $ 2 (2)          
Issuance of common stock in exchange for exercise of cashless warrants (in shares) 2,317,085            
Employee stock purchase plan   31         31
Employee stock purchase plan (in shares) 2,558            
Stock-based compensation   1,457         1,457
Foreign currency transaction loss     (5)       (5)
Net loss       (28,618)     (28,618)
Balance, at end at Dec. 31, 2019 $ 9 226,524 (46) (217,070)     9,417
Balance, at end (in shares) at Dec. 31, 2019 8,531,504            
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock in exchange for exercise of warrants in February and March 2020 ($0.57 per share) $ 13 7,461         7,474
Issuance of common stock in exchange for exercise of warrants in February and March 2020 ($0.57 per share) (in shares) 13,111,999            
Deemed dividend in connection with repricing of November 2019 warrants   451         451
Warrant deemed dividend   (451)         (451)
Issuance of common stock in March 2020 net of transactional expenses of $1,221 $ 14 14,770         14,784
Issuance of common stock in March 2020 net of transactional expenses of $1,221(in shares) 14,550,000            
Issuance of common stock in June 2020 under the equity line $ 1 277         278
Issuance of common stock in June 2020 under the equity line (in shares) 464,471            
Issuance of common stock under At-the-market offering, net of transaction expenses of $2,304 $ 102 68,700         68,802
Issuance of common stock under At-the-market offering, net of transaction expenses of $2,304 (in shares) 102,676,174            
Beneficial conversion feature in connection with issuance of Series B Convertible preferred stock   1,260         1,260
Issuance of common stock in the acquisition of Trigemina assets $ 2 1,358         1,360
Issuance of common stock in the acquisition of Trigemina assets (in shares) 2,000,000            
Issuance of common stock in July 2020 net of transactional expenses of $829 $ 21 9,620         9,641
Issuance of common stock in July 2020 net of transactional expenses of $829 (in shares) 20,940,000            
Issuance of common stock in exchange for exercise of warrants in July and August 2020 (see note 13) $ 5 2,417         2,422
Issuance of common stock in exchange for exercise of warrants in July and August 2020 (see note 13) (in shares) 4,533,404            
Issuance of common stock under 2020 Purchase Agreement $ 26 14,548         14,574
Issuance of common stock under 2020 Purchase Agreement (in shares) 25,441,500            
Preferred stock deemed dividend   (1,260)         (1,260)
Issuance of common stock and common stock warrants in February 2020 net of transactional expenses of $292 $ 4 1,891         1,895
Issuance of common stock and common stock warrants in February 2020 net of transactional expenses of $292 (in shares) 3,837,000            
Issuance commitment under 2020 Purchase Agreement (in shares) 600,000            
Issuance of Series B Convertible preferred stock and common stock warrants in February 2020 ($1,000.00 per share, net of transactional expenses of $711)   4,602         4,602
Issuance of Series B Convertible preferred stock and common stock warrants in February 2020 ($1,000.00 per share, net of transactional expenses of $711) (in shares)           5,313  
Issuance of common stock upon conversion of Series B Convertible preferred stock $ 9 (9)          
Issuance of common stock upon conversion of Series B Convertible preferred stock (in shares) 9,321,053         (5,313)  
Employee stock purchase plan   2         2
Employee stock purchase plan (in shares) 1,578            
Stock-based compensation   2,876         2,876
Foreign currency transaction loss     (16)       (16)
Net loss       (50,463)     (50,463)
Balance, at end at Dec. 31, 2020 $ 206 $ 355,037 $ (62) $ (267,533)     $ 87,648
Balance, at end (in shares) at Dec. 31, 2020 206,008,683